

CLINICAL *Trials*



Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding these clinical trials, please contact 313-576-9790.

DECEMBER 2019

**SUBSCRIBE TO
KARMANOS CLINICAL TRIALS**

To view the current issue online, please [click here](#).



Get access to our clinical trials on your iPhone®, iPad® or Android™ mobile devices with the FREE KCI Trials App.

Bone Marrow Transplant	Gynecologic	Immunotherapy	Phase 1
Breast	Head & Neck	Melanoma/Skin	Sarcoma
Gastrointestinal	Hematology	Neuro-Oncology	Thoracic
Genitourinary			

Bone Marrow Clinical Trials

For more information on Bone Marrow Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this [online referral form](#).

BONE MARROW TRANSPLANT

STUDY 2018-145

Phase III

Tisagenlecleucel versus Standard of Care in Adult Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)

STUDY 2019-024

Phase I/II

An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)

STUDY 2018-084

Phase I/II

A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease

STUDY BMTCTN1506

Phase III

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML.

STUDY 2017-081

Phase III

Phase 3 Randomized Trial of Carfilzomib, Lenalidomide, Dexamethasone versus Lenalidomide Alone after Stem-Cell Transplant for Multiple Myeloma

STUDY 2014-103

Phase I/II

A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

STUDY 2016-049

Phase I/II

A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune (ex vivo Programmed Mobilized Peripheral Blood Cells) Versus Non- Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects with Hematologic Malignancies

STUDY 2016-209

Phase II

A Phase II Trial of CD24Fc for Prevention of Acute Graft-versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplant

STUDY NEW A051301

Phase III

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype

STUDY BMTCTN1703

Phase III

A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation

STUDY 2019-005

Phase III

A Global Randomized Multicenter Phase 3 Trial to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects with High-Risk, Transplant-Eligible Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (TRANSFORM)

STUDY 2011-086

NA

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications.

STUDY NEW 2019-100

Phase III

A Randomized, Double-Blind, Placebo-Controlled, Mutlicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft-Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

[RETURN TO TOP](#)

Breast Clinical Trials

For more information on Breast Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this [online referral form](#).

ADJUVANT

STUDY NRG-BR003

Phase III

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

STUDY A011502

Phase III

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial

STUDY 2017-129

NA

Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List.

ADJUVANT HORMONAL

STUDY 2017-129

NA

Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List.

ADJUVANT RADIATION

STUDY 2017-129

NA

Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List.

NEOADJUVANT

STUDY RTOG1304

Phase III

NSABP B-51 RTOG1304: A Randomized Phase III Clinical Trial Evaluating Post Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy.

STUDY S1418

Phase III

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy.

STUDY EA1131

Phase III

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients with Residual Triple-Negative Breast Cancer following Neo-adjuvant Chemotherapy

STUDY 2017-129

NA

Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List.

ADVANCED (STAGE IV) CHEMOTHERAPY

STUDY 2017-129**NA**

Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List.

STUDY 2018-009**Phase II**

A Phase II Open-Label, Randomized Study of PARP inhibition (olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-positive Breast Cancer

STUDY 2018-015**Phase I/II**

A Phase 1b/2 Study to Evaluate Safety and Anti Tumor Activity of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors

STUDY 2017-064**Phase I/II**

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

STUDY 2019-043**Phase III**

Elacestrant Monotherapy VS. Standard of care for the Treatment of Patients with ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-Label, Active-Controlled, Multicenter Trial (EMERALD)

STUDY NRG-BR004**Phase III**

A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

STUDY 2018-054**Phase I**

A Phase 1a/1b Study of FPA150, and Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors

HORMONAL**STUDY 2017-129****NA**

Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List.

STUDY A17160**Phase II**

A Phase II Trial Assessing the Tolerability of Palbociclib in Combination With Letrozole or Fulvestrant in Patients Aged 70 and Older With Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer

OTHERS**STUDY 2016-055****Phase I**

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY S1501**Phase III**

Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III

STUDY 2017-073**Phase II**

The Effect of Statins on Markers of Breast Cancer Proliferation and Apoptosis in Women with Early Stage Breast Cancer

STUDY A011401**Phase III**

Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer

STUDY 2016-116**Phase II**

A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors

STUDY 2017-029**Phase I**

An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours

STUDY 2018-141**Phase I/II**

A Phase 1b/2a Two-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination with Gemcitabine in Patients with Advanced or Metastatic Cancer

STUDY 2018-062**NA**

Reducing Metabolic Syndrome and Unmet needs Among Rural Breast Cancer Survivors During the Survivorship Transition

STUDY 2018-015**Phase I/II**

A Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors

STUDY 2016-037**Phase I**

A Phase I Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

[RETURN TO TOP](#)

Gastrointestinal Clinical Trials

For more information on Gastrointestinal Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this [online referral form](#).

ESOPHAGUS**Metastatic****STUDY 2017-064****Phase I/II**

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

STUDY 2019-088**Phase III**

A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination with Chemotherapy as First-Line Treatment in Patients with Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

GASTRIC AND GASTROESOPHAGEAL JUNCTION

Metastatic

STUDY 2016-210

Phase I/II

An Open-Label, Dose-Finding And Proof Of Concept Study Of The PD-L1 Probody Therapeutic, CX-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas

STUDY 2017-150

Phase I/II

A Phase 1/2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

STUDY 2017-064

Phase I/II

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

STUDY 2018-088

Phase III

A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2 Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

STUDY 2017-029

Phase I

An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours

STUDY 2016-003

Phase I/II

A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

STUDY 2016-037

Phase I

A Phase I Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

STUDY 2017-087

Phase I

An Open-Label, Phase I Trial to Determin The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumors

PANCREAS

Adenocarcinoma

Locally Advanced Unresectable

STUDY 2018-048

Phase III

PANOVA-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Gemcitabine and nab-Paclitaxel for Font-Line Treatment of Locally-Advanced Pancreatic Adenocarcinoma

STUDY 2018-076

Phase I/II

A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas

Metastatic

STUDY 2017-069

Phase I/II

A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2019-002**Phase III**

A Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenocarcinoma of the Pancreas

STUDY 2016-116**Phase II**

A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors

STUDY 2019-001**Phase II**

A Phase IIA, Multicenter, Open-Label Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Subjects with Metastatic Pancreatic Cancer, The Combat Study

STUDY 2018-166**Phase I/II**

A Phase 1/2 Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GP-2250 in Combination with Gemcitabine in Subjects with Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma Who Have Progressed on Prior Treatment with FOLFIRINOX Chemotherapy

STUDY 2018-076**Phase I/II**

A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas

STUDY 2018-090**Phase III**

A Randomized Controlled, Open label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine versus Gemcitabine alone in Patients with Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment

STUDY NEW 2019-088**Phase I/II**

A Phase 1b/2, Open-Label, Multicenter Dose Escalation and Dose-Expansion Study of the Combination of RMC-4630 and Cobimetinib in Adults Participants With Relapsed/Refractory Solid Tumors With Specific Genomic Aberrations

HCC**Adjuvant****STUDY 2019-048****Phase III**

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma

STUDY RTOG1112**Phase III**

Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Phase III Therapy Followed By Sorafenib in Hepatocellular Carcinoma

Metastatic**STUDY 2017-064****Phase I/II**

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

BILIARY/GALL BLADDER

Metastatic

STUDY 2019-009

Phase III

A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement

STUDY S1815

Phase III

A Phase III Randomized Trial of Gemcitabine, Cisplatin, and NAB-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

STUDY 2014-081

Phase II

A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients with Advanced or Metastatic Cholangiocarcinoma with FGFR2 Gene Fusions or other FGFR Genetic Alterations who Failed or Are Intolerant to Platinum-Based Chemotherapy

COLON

Adjuvant

STUDY A021502

Phase III

Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy of Patients with Stage III Colon Cancer with Deficient DNA Mismatch Repair

Metastatic (Includes Rectal)

1st Line

STUDY NRG-GI004

Phase III

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

Metastatic (Includes Rectal)

2nd Line

STUDY 2016-055

Phase I

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY 2016-157

Phase I

Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

STUDY 2019-010

Phase III

A Randomized, Multicenter, Parallel-Group, Phase III Study to Compare the Efficacy of Arfollitoxorin versus Leucovorin in Combination with 5-fluorouracil, Oxaliplatin, and Bevacizumab in Patients with Advanced Colorectal Cancer

STUDY 2018-021**Phase II**

A Phase 2, Multicenter, Open-Label Study of DS-8201A in Subjects with HER2- Expressing Advanced Colorectal Cancer

STUDY 2016-003**Phase I/II**

A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

STUDY 2016-037**Phase I**

A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

STUDY 2017-129**NA**

Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List

STUDY NEW 2019-088**Phase I/II**

A Phase 1b/2, Open-Label, Multicenter Dose Escalation and Dose-Expansion Study of the Combination of RMC-4630 and Cobimetinib in Adults Participants With Relapsed/Refractory Solid Tumors With Specific Genomic Aberrations

RECTUM**STUDY 2017-129****NA**

Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List

STUDY EA2165**Phase II**

A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

ANAL**Metastatic****STUDY EA2165****Phase II**

A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

STUDY 2018-122**Phase II**

A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal

IMAGING STUDIES**Metastatic****STUDY 2018-171****Phase II**

A Phase II, Open Label, Multi-Dose Study of 89ZR-DF-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients with Metastatic Solid Tumors

STUDY 2006-127

NA

Use of [F-18] FLT for Imaging with Positron Emission Tomography (PET)

OTHER**STUDY 2017-064****Phase I/II**

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

[RETURN TO TOP](#)

Genitourinary Clinical Trials

For more information on Genitourinary Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this [online referral form](#).

RENAL**STUDY 2016-003****Phase I/II**

A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

STUDY 2016-037**Phase I**

A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors

STUDY EA8143**Phase III**

A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

STUDY 2019-084**Phase III**

A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk

STUDY S1500**Phase II**

A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)

STUDY 2017-082**Phase I/II**

A Phase I/II Trial of Pazopanib Alternating with Bevacizumab in Treatment-Naïve Metastatic Clear Cell Renal Cell Carcinoma Patients

STUDY 2017-069**Phase I/II**

A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2017-111**Phase I**

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

STUDY 2016-211**Phase II**

A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma (FRACTION-RCC)

STUDY 2017-029**Phase I**

An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours

STUDY 2016-157**Phase I**

Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

STUDY 2017-064**Phase I/II**

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

STUDY 2016-055**Phase I**

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY 2018-098**Phase I/II**

A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Anti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected Solid Tumors

PROSTATE**STUDY 2013-108****NA**

Immune Evaluation Study of Sipuleucel-T in African American and Non African American Men with Castrate Resistant Prostate Cancer

STUDY 2016-157**Phase I**

Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

STUDY 2019-029**Phase III**

A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)

STUDY 2018-170**NA**

Genetic Counseling Processes and Outcomes Among Males with Prostate Cancer (ProGen)

STUDY NEW 2019-027**Phase II**

IMPACT: Immunotherapy in Patients with Metastatic Cancers and CDK12 Mutations

STUDY 2019-030**Phase III**

A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE-921)

STUDY 2019-045**Phase II**

A Multicentre Phase IIb Trial to Evaluate the Efficacy and Tolerability of ModraDoc006/r in Subjects with Metastatic Castration Resistant Prostate Cancer (mCRPC), Suitable for Treatment with a Taxane

STUDY 2019-007**Phase I/II**

A Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination with the Anti-Programmed Cell Death 1 (PD-1) Monoclonal Antibody Pembrolizumab (PEMBRO; Keytruda®) in Patients with Small Cell Neuroendocrine Prostate Cancer (SCNC; NEPC)

STUDY 2019-047**Phase I/II**

A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE)

STUDY 2018-163**Phase I**

A Phase 1 Study of FOR46 Administered Every 21 Days in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

STUDY NRG-GU002**Phase II/III**

Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel

STUDY 2018-124**Phase I/II**

Phase 1/2a Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CORT125281 with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

STUDY S1802**Phase III**

Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer.

STUDY 2018-173**Phase III**

The MAP TRIAL: Phase III Study of Muscadine Plus (MPX) in Men with Prostate Cancer: A Randomized Double-Blind, Placebo-Controlled Study of the Effects of MPX Capsules on Rising Prostate-Specific Antigen Levels in Alanine/Alanine SOD2 Genotype Men Following Initial Therapy for Prostate Cancer

STUDY 2017-126**Phase II**

Phase II Study of Olaparib in Men with High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, with Integrated Biomarker Analysis

STUDY EA8153**Phase II**

Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: Phase II the CHARTED2 Trial

STUDY NRG-GU005**Phase III**

Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer

STUDY 2015-135**Phase II**

Phase II Trial of Immune Checkpoint Inhibitor with Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells in Metastatic Castrate Resistant Prostate Cancer.

STUDY 2017-092**Phase II**

A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy

STUDY 2015-167**Phase II**

A Randomized Phase 2 Trial of Ascorbic Acid in Combination with Docetaxel in Men with Metastatic Prostate Cancer

STUDY 2017-046**Phase I**

A Phase IB Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination with Androgen Deprivation Therapy and Other Agents in Subjects with Castrate Resistant Prostate Cancer (CRPC)

STUDY 2015-029**Phase II**

Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men with High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy

STUDY 2018-015**Phase I/II**

A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors

STUDY 2017-156**Phase II**

A Phase II Open-Label, a Multisite Study of Apalutamide, Abiraterone and Prednisone in African American and Caucasian Men with Metastatic Castrate Resistant Prostate Cancer

STUDY 2017-129**NA**

Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List

STUDY 2018-017**Phase II**

A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Doxorubicin, or Enzalutamide in Men with Castration Resistant Metastatic Prostate Cancer (CheckMate 9KD: CHECKpoint Pathway and NivolumAb Clinical Trial Evaluation 9KD)

STUDY NEW 2019-031**Phase II**

Phase II Multi-center Trial of ESK981 in combination with Nivolumab in Patients with Metastatic Castrate Resistant Prostate Cancer

BLADDER**STUDY 2016-055****Phase I**

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY 2017-070**Phase II**

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin(BCG) in Combination with ALT-803 in Patients with BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

STUDY 2017-064**Phase I/II**

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

STUDY 2019-019**Phase II**

A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy

STUDY 2016-195**Phase II**

Phase II Trial of Concurrent Nivolumab in Urothelial Bladder Cancer with Radiation Therapy in Localized/Locally Advanced Disease for Chemotherapy Ineligible Patients [NUTRA]

STUDY 2018-110**Phase II**

A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma

STUDY 2016-003**Phase I/II**

A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

STUDY 2019-081**Phase II**

A Phase 2, Multicenter, Randomized, Double-Blind, Active-Control Study to Evaluate the Efficacy and Safety of Nivolumab Administered in Combination with IPI-549 Compared to Nivolumab Monotherapy in the Treatment of Patients with Immune Therapy-Naïve, Advanced Urothelial Carcinoma

STUDY 2015-101**Phase I/II**

A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 in patients with BCG-naïve Non-Muscle Invasive Bladder Cancer

STUDY 2017-092**Phase II**

A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy

STUDY 2017-069**Phase I/II**

A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2017-029**Phase I**

An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours

STUDY 2018-165**Phase III**

A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer (NIAGARA)

STUDY 2016-175**Phase II**

A Randomized Phase 2 Trial of Cisplatin/Gemcitabine with or without VX-970 in Metastatic Urothelial Carcinoma

STUDY 2016-157**Phase I**

Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

STUDY 2018-044**Phase II**

Phase 2 Trial of Olaparib in Patients with Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

STUDY 2018-015**Phase I/II**

A Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors

STUDY 2016-037**Phase I**

A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

STUDY NEW 2018-023**Phase I/II**

An International, Multicenter, Phase 1b/2 Study of Rogaratinib (BAY 1163877) in Combination with Atezolizumab as First-line Treatment in Cisplatin-Ineligible Patients with FGFR-positive locally advanced or metastatic urothelial carcinoma

STUDY 2018-098**Phase I**

A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Anti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected Solid Tumors

STUDY S1806**Phase III**

Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer

STUDY 2018-171**Phase II**

A Phase II, Open-Label, Multi-Dose Study of 89ZR-DF-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients with Metastatic Solid Tumors

OTHER**STUDY 2018-171****Phase II**

A Phase II, Open Label, Multi-Dose Study of 89ZR-DF-IAB22M2C (CD8 PE Tracer) for Positron Emission Tomography (PET/CT) in Patients with Metastatic Solid Tumors

[RETURN TO TOP](#)

Gynecologic Clinical Trials

For more information on Gynecologic Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this [online referral form](#).

CERVIX**STUDY 2017-010****Phase II**

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma

STUDY 2017-064**Phase I/II**

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

STUDY 2018-103**Phase III**

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)

STUDY 2017-069**Phase I/II**

A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

OVARY**STUDY GOG-3020****Phase III**

ATHENA: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

STUDY 2018-043**Phase III**

A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer

STUDY GOG-3018**Phase III**

The OVAL Study: A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

STUDY 2018-159**Phase II**

Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen

STUDY NRG-GY005**Phase II/III**

Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib Alone or Olaparib Alone or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer

STUDY 2018-141**Phase I/II**

A Phase 1b/2a Two-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination with Gemcitabine in Patients with Advanced or Metastatic Cancer

STUDY 2017-064**Phase I/II**

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

STUDY 2016-037**Phase I**

A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors

STUDY 2018-054**Phase I**

A Phase 1a/1b Study of FPA 150, an Anti-B7-H4 Antibody, in Patients With Solid Advanced Tumors

STUDY 2018-015**Phase I/II**

A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors

STUDY 2017-029**Phase I**

An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy of BI 754091 In Patients With Advanced Solid Tumors

STUDY 2019-046**Phase I/II**

Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine with or without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer

STUDY NEW NRG-GY019**Phase III**

A Randomized, Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-grade Serous Carcinoma of the Ovary or Peritoneum

UTERUS**STUDY 2017-064****Phase I/II**

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

STUDY 2018-141**Phase I/II**

A Phase 1b/2a Two-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination with Gemcitabine in Patients with Advanced or Metastatic Cancer

STUDY NEW 2019-107**Phase II**

A Phase II Study of the PARP inhibitor Olaparib in Combination with the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma

OTHER**STUDY 2018-054****Phase I**

A Phase 1a/1b Study of FPA 150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors

STUDY 2019-046**Phase I/II**

Phase I Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine with or without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer

STUDY NEW NRG-GY019**Phase III**

A Randomized, Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-grade Serous Carcinoma of the Ovary or Peritoneum

STUDY GOG-3031**Phase III**

A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-paclitaxel versus Placebo plus Carboplatin-paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer (RUBY)

[RETURN TO TOP](#)

Head & Neck Clinical Trials

For more information on Head & Neck Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this [online referral form](#).

STAGES I/II/III

STUDY 2016-093

Phase I/II

A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

STUDY EA3132

Phase II

Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing

STUDY 2018-117

Phase II

The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN).

STUDY 2017-157

Phase III

A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

STUDY EA3163

Phase II

Phase II Randomized Trial of Neo-Adjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)

STUDY RTOG1008

Phase II/III

A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors

STUDY NRG-HN001

Phase II/III

Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

STUDY 2019-083

Phase II

A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors

STUDY NEW EA3161

Phase II/III

Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA

STUDY 2019-069

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy

ANY STAGE

STUDY 2016-212**Phase II**

A Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-145) followed by IL-2 in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

STUDY 2017-107**Phase III**

A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942(Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck

STUDY 2019-087**Phase I**

A Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Patients with HPV+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

STUDY 2018-076**Phase I/II**

A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas

STUDY 2017-069**Phase I/II**

A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2016-017**Phase I/II**

A Phase 1B/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab* (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies

STUDY 2018-098**Phase I/II**

A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Anti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected Solid Tumors

OTHER**STUDY 2017-064****Phase I/II**

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

STUDY 2016-055**Phase I**

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY 2018-171**Phase II**

A Phase II, Open Label, Multi-Dose Study of 89ZR-DF-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients with Metastatic Solid Tumors

STUDY 2016-037**Phase 1**

A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

STUDY 2017-087**Phase I**

A Phase 1, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult Patients with Advanced Malignancies

[RETURN TO TOP](#)

Hematology Clinical Trials

For more information on Hematology Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this [online referral form](#).

MULTIPLE MYELOMA

STUDY 2012-122

Phase I/II

Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment with Pomalidomide, Dexamethasone, and Carfilzomib (PdC) in Subjects with Relapsed and Relapsed/Refractory Multiple Myeloma

STUDY 2019-071

Phase I/II

A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC- 92480 in Combination with Standard Treatments in Subjects with Relapsed or Refractory (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

STUDY 2018-112

Phase I

A Phase 1 Study of FOR46 Administered Every 21 Days in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

STUDY 2016-062

Phase I/II

Phase 1/2 Trial of Idasanutlin in Combination with Ixazomib and Dexamethasone in Patients with 17p Deleted, Relapsed Phase I/II Multiple Myeloma

STUDY 2017-136

Pilot

An Open-label, Pilot Study of Dabrafenib and/or Trametinib in Patients with Relapsed and/or Refractory Multiple Myeloma

STUDY 2018-014

Phase I

A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MEDI2228 in Subjects with Relapsed/Refractory Multiple Myeloma

STUDY 2018-028

Phase II

A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens

STUDY 2016-086

Phase I

A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-220 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma

STUDY 2018-026

Phase II

A Phase II Study of CD38 Antibody Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

STUDY 2018-176

Phase I/II

MyDRUG: Myeloma-Developing Regimens Using Genomics (Genomics Guided Multi-arm Trial of Targeted Agents Alone or in

Combination with a Backbone Regimen)

STUDY 2019-054

Phase II

A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment

STUDY S1803

Phase III

Phase III Study of Daraumumab/rGuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMATIC Study)

STUDY 2019-014

Phase II

Open-Label, Single-arm, Phase 2 Study of Initial Treatment with Elotuzumab, Carfilzomib (Kyprolis), Lenalidomide (Revlimid) and Low dose Dexamethasone (E-KRd) in Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy

STUDY 2018-042

Phase III

A Phase 3, Multicenter, Randomized, Open-Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14) Positive Relapsed or Refractory Multiple Myeloma

STUDY 2019-006

Phase I/II

Phase 1/2 FIH Study of REGN5458 (Anti-CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma

AMYLOIDOSIS or LIGHT CHAIN DEPOSITION DISEASE

STUDY 2016-200

Phase II

A Randomized Phase 2 Trial of Revlimid/ Dexamethasone/ Elotuzumab +/- Cyclophosphamide followed by Revlimid/ Dexamethasone/Elotuzumab Maintenance as Second-line Therapy for Patients with Relapsed AL Amyloidosis

STUDY 2016-060

Phase I

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-63709178, a Humanized CD123x CD3 DuoBody in Subjects with Relapsed or Refractory AML

LUEKEMIA

Acute Myeloid Leukemia (AML)

STUDY BMTCTN1506

Phase III

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML.

STUDY 2018-027

Phase I/II

A Phase I/II, Open-Label, Multicenter 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle in Patients with Relapsed Acute Myeloid Leukemia/High-Risk Myelodysplastic Syndrome or Treatment-Naïve Patients Not Eligible for Intensive Induction Therapy

STUDY 2017-119

Phase III

Phase III Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crenolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects < or = 75 Years of Age with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia

STUDY 2015-093**Phase II**

Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy

STUDY 2019-023**Phase I**

A Phase 1, First-in-Human, Dose Escalation Study of JNJ-67571244 (bispecific antibody targeting CD33 and CD3) in Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

STUDY 2017-120**Phase III**

Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia

STUDY 2016-035**Phase I**

A Phase 1/1b, Multicenter, Open-label, Dose-Escalation Study of FT-2102 as a Single Agent and in Combination with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation

Chronic Lymphocytic Leukemia (CLL)**STUDY 2014-132****Phase III**

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

STUDY EA9161**Phase III**

A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

STUDY A041702**Phase III**

A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (greater than or equal to 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Chronic Myeloid Leukemia (CML)**STUDY 2015-128****Phase II**

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

LYMPHOMA**Hodgkin's****STUDY 2017-132****Phase II**

An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)

STUDY 2019-074**Phase II**

A Phase 2, Multicenter, Single-arm Study of Retreatment with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) or CD30-Expressing Peripheral T Cell Lymphoma (PTCL)

STUDY 2016-033**Phase II**

A Phase II Multicenter Single Arm Study to Evaluate the Efficacy and Safety of Single Agent Bruton's Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with Relapsed Refractory Hodgkin's Lymphoma

STUDY NEW S1826**Phase III**

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age \geq 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

STUDY 2019-102**Phase II**

A Phase 2 Open-Label Study of Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T Cell Lymphoma (PTCL) In Adults Age 60 and Above

Non-Hodgkin's**Aggressive (Mantle Cell, Large B-Cell Lymphoma)****STUDY 2013-047****Phase I**

A Phase 1 Multiple Ascending Dose Study of DS-3032B, an Oral MDM2 Inhibitor, in Subjects with Advanced Solid Tumors or Lymphomas

STUDY 2018-094**Phase I/II**

An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Mosunetuzumab (Btct4465a) In Combination With Polatuzumab Vedotin In Patients With B-Cell Non-Hodgkin Lymphoma

STUDY 2015-150**Phase I/II**

A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination with Polatuzumab Vedotin and Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma and Rituximab in Combination with Polatuzumab Vedotin and Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

STUDY 2014-132**Phase III**

A Phase 3b, Multicenter, Open-Label, PCI-32765 (Ibrutinib) Long-term Extension Study

T cell**STUDY 2016-210****Phase I/II**

An Open-Label, Dose-Finding And Proof Of Concept Study Of The PD-L1 Probody Therapeutic, CX-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas

STUDY 2016-056**Phase II**

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

STUDY 2018-003**Phase I**

A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in Patients with Advanced Relapsed or Refractory Lymphoma or Myeloma

STUDY 2018-076**Phase I/II**

A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas

STUDY 2019-074**Phase II**

A Phase 2, Multicenter, Single-arm Study of Retreatment with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) or CD30-Expressing Peripheral T Cell Lymphoma (PTCL)

STUDY 2018-119**Phase I/II**

Phase I/II Study of Ixazomib and Romidepsin in Relapsed/ Refractory Peripheral T-cell Lymphoma (PTCL)

STUDY 2017-069**Phase I/II**

A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2016-037**Phase I**

A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

STUDY 2019-102**Phase II**

A Phase 2 Open-Label Study of Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T Cell Lymphoma (PTCL) In Adults Age 60 and Above

MYELODYSPLASTIC SYNDROME (MDS)**STUDY 2016-035****Phase I**

A Phase 1/1b, Multicenter, Open-label, Dose-Escalation Study of FT-2102 as a Single Agent and in Combination with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation

STUDY 2019-023**Phase I**

A Phase 1, First-in-Human, Dose Escalation Study of JNJ-67571244 (bispecific antibody targeting CD33 and CD3) in Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Study 2018-027**Phase I/II**

A Phase I/II, Open-Label, Multicenter 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle in Patients with Relapsed Acute Myeloid Leukemia/High-Risk Myelodysplastic Syndrome or Treatment-Naive Patients Not Eligible for Intensive Induction Therapy

OTHER**STUDY 2013-113****Phase II**

A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia

STUDY 2019-057**Phase II**

A Phase 2 Study of the Heparin Mimetic PTG-300 in Patients with Phlebotomy-Requiring Polycythemia Vera

STUDY NEW 2019-100**Phase III**

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft-Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

[RETURN TO TOP](#)

Immunotherapy Clinical Trials

For more information on Immunotherapy Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

IMMUNOTHERAPY

STUDY 2018-015

Phase I/II

A Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors

[RETURN TO TOP](#)

Melanoma/Skin Clinical Trials

For more information on Melanoma/Skin Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this [online referral form](#).

ADVANCED

STUDY 2016-210

Phase I/II

An Open-Label, Dose-Finding And Proof Of Concept Study Of The PD-L1 Probody Therapeutic, CX-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas

STUDY 2017-029

Phase I

An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumors

STUDY 2017-064

Phase I/II

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

STUDY 2017-069

Phase I/II

A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2016-037

Phase I

A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors

STUDY EA6134

Phase III

A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

STUDY 2013-047

Phase I

A Phase 1 Multiple Ascending Dose Study of DS-3032B, an Oral MDM2 Inhibitor, in Subjects with Advanced Solid Tumors or Lymphomas

STUDY 2016-017

Phase I/II

A Phase 1B/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab* (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies

STUDY 2018-098

Phase I/II

A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Anti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected Solid Tumors

STUDY 2017-087

Phase I

A Phase 1, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult Patients with Advanced Malignancies

OTHER

STUDY 2017-029

Phase I

An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours

STUDY 2017-064

Phase I/II

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

STUDY 2016-055

Phase I

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

[RETURN TO TOP](#)

Neuro-Oncology Clinical Trials

There are currently no open clinical trials. For more information on Karmanos Clinical Trials please contact the Karmanos Clinical Trials Office at 313-576-9790.

[RETURN TO TOP](#)

Phase I Clinical Trials

For more information on Phase 1 Clinical Trials or to refer a patient, please call 313-576-9204 or email Phase1NewPt@karmanos.org. All patients will need to go through an initial new patient screening consultation to determine if they are eligible for one of our Phase 1 studies and to ensure that it is the best treatment option available for them.

ALL SOLID TUMORS

STUDY 2017-111

Phase I

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

STUDY 2017-122

Phase I

A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

STUDY 2018-019

Phase I

A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0337 in Patients with Advanced Solid Tumors

STUDY 2018-076

Phase I/II

A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas

STUDY 2018-156

Phase 1

A Phase 1 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

STUDY 2016-170

Phase I/II

A Phase I/IIa, Open-Label, Dose-escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients with Advanced Malignancy

STUDY 2018-104

Phase I/II

A Phase I-II, First-in-Human Study of A166 in Patients with Locally Advanced/Metastatic Solid Tumors which are Human Epidermal Growth Factor Receptor 2 (HER2)-Positive who did not Respond or Stopped Responding to Approved Therapies and Patients with HER2 Positive (by ISH or NGS) or Low Expressing (by IHC) Solid Tumors who did not Respond or Stopped Responding to Approved Therapies

STUDY 2016-210

Phase I/II

An Open-Label, Dose-Finding And Proof Of Concept Study Of The PD-L1 Probody Therapeutic, CX-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas

STUDY 2018-034

Phase I

A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

STUDY 2017-088

Phase I

A Phase 1 Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

STUDY 2017-052

Phase I/II

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors

STUDY 2016-157

Phase I

Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

STUDY 2018-154

Phase I

A Phase 1/1b Open-Label Multi-Center to Characterize the Safety and Tolerability of TRQ15-01 in Patients with Relapsed/Refractory Metastatic or Locally-Advanced Solid Tumor or Lymphoma

STUDY 2018-158

Phase I/II

First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients with Advanced/Metastatic Solid Tumors

STUDY 2016-037

Phase I

A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors

STUDY 2018-066**Phase I**

A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb@20717 in Subjects with Selected Advanced Solid Tumors (DUET-2)

STUDY 2018-035**Phase I**

A Phase 1, Multi-Center, Open-Label, Single-Arm, Dose-Escalation, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-Tumor Activity of FN-1501 Monotherapy in Patients with Advanced Solid Tumors

STUDY 2018-054**Phase I**

A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors

STUDY 2018-157**Phase I**

An Open Label, Dose-Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-981 in Adult Patients With Metastatic Solid Tumors or Lymphomas

STUDY 2017-086**Phase I/II**

A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors

STUDY 2018-100**Phase I**

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB001 in Subjects with Advanced Malignancies

STUDY 2018-109**Phase I/II**

A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001)

STUDY NEW 2019-082**Phase I**

A Phase 1, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of PSB205 in Patients with Relapsed/Refractory Solid Tumors

STUDY 2017-087**Phase I**

A Phase 1, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult Patients with Advanced Malignancies

TUMOR SPECIFIC**STUDY 2016-210****Phase I/II**

An Open-Label, Dose-Finding And Proof Of Concept Study Of The PD-L1 Probody Therapeutic, CX-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas

STUDY 2018-157**Phase I**

An Open Label, Dose-Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-981 in Adult Patients With Metastatic Solid Tumors or Lymphomas

STUDY 2019-023**Phase I**

A Phase 1, First-in-Human, Dose Escalation Study of JNJ-67571244 (bispecific antibody targeting CD33 and CD3) in Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

STUDY 2017-064**Phase I/II**

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

STUDY 2018-076**Phase I/II**

A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas

STUDY 2019-071**Phase I/II**

A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC- 92480 in Combination with Standard Treatments in Subjects with Relapsed or Refractory (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

STUDY 2018-141**Phase I/II**

A Phase 1b/2a Two-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination with Gemcitabine in Patients with Advanced or Metastatic Cancer

STUDY 2018-163**Phase I**

A Phase 1 Study of FOR46 Administered Every 21 Days in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

STUDY 2019-007**Phase I/II**

A Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination with the Anti-Programmed Cell Death 1 (PD-1) Monoclonal Antibody Pembrolizumab (PEMBRO; Keytruda®) in Patients with Small Cell Neuroendocrine Prostate Cancer (SCNC; NEPC)

STUDY 2018-138**Phase I/II**

An Open-Label Phase 1B/2 Study to Evaluate the Safety and Efficacy of Tabelecleucel in Combination with Pembrolizumab in Subjects with Platinumpretreated, Recurrent/Metastatic Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma

STUDY 2019-026**Phase I**

A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination with Pembrolizumab in Subjects with Selected Advanced Solid Tumors (DUET-4)

STUDY 2018-120**Phase I/II**

An Open Label, Single Arm, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination with Pembrolizumab in Patients with Advanced or Metastatic Post-PD-1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma

STUDY 2016-037**Phase I**

A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors

STUDY 2018-166**Phase I/II**

A Phase 1/2 Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GP-2250 in Combination with Gemcitabine in Subjects with Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma Who Have Progressed on Prior Treatment with FOLFIRINOX Chemotherapy

STUDY 2013-047**Phase I**

A Phase 1 Multiple Ascending Dose Study of DS-3032B, an Oral MDM2 Inhibitor, in Subjects with Advanced Solid Tumors or Lymphomas

STUDY 2017-029**Phase I**

An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours

STUDY 2019-053**Phase I**

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ- 61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer

STUDY 2017-069**Phase I/II**

A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2016-055**Phase I**

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY 2018-015**Phase I/II**

A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors

STUDY 2018-098**Phase I/II**

A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Anti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected Solid Tumors

STUDY NEW 2019-088**Phase I/II**

A Phase 1b/2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 and Cobimetinib in Adult Participants with Relapsed/Refractory Solid Tumors with Specific Genomic Aberrations

STUDY 2019-047**Phase I/II**

A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE)

STUDY 2019-070**Phase I**

Phase 1 Study of KN026 in HER2 Expressing Breast Cancer, Gastic/Gastroesophageal Junction Cancer and other Locally Advanced/Metastatic Solid Tumors

GENOMIC TESTING SPECIFIC**STUDY 2016-157****Phase I**

Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

STUDY 2018-054**Phase I**

A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors

STUDY 2018-015**Phase I/II**

A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Or Metastatic Solid Tumors

[RETURN TO TOP](#)

Sarcoma Clinical Trials

There are currently no open clinical trials. For more information on Karmanos Clinical Trials please contact the Karmanos Clinical Trials Office at 313-576-9790.

[RETURN TO TOP](#)

Thoracic Clinical Trials

For more information on Thoracic Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this [online referral form](#).

ADJUVANT

STUDY 2018-142

Phase III

A Phase III, Double-blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-**Based** Chemotherapy in Patients with Resectable Stage II, IIIA, or SELECT IIIB Non-Small Cell Lung Cancer

MAINTENANCE

STUDY NRG-LU002

Phase II/III

Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Trial

STUDY NRG-LU004

Phase I

Phase I Trial of Accelerated or Conventionally Fractionated Radiotherapy Combined With MEDI4736 (Durvalumab) in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1)

STAGE I/II

STUDY 2016-110

Phase II

A Phase II, Open-label, Multicenter, Single-arm Study To Investigate The Efficacy And Safety Of Atezolizumab As Neoadjuvant And Adjuvant Therapy In Patients With Stage IB, II, Or IIIA Resectable And Untreated Non-Small Cell Lung Cancer

STUDY 2019-018

Phase I/II

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

STUDY 2019-053

Phase I

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ- 61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer

STUDY 2018-098

Phase I/II

A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Anti-Tumor Activity of GEN-009 Adjuvanted in Adult Patients with Selected Solid Tumors

STAGE III A/B
STUDY 2016-110

Phase II

A Phase II, Open-label, Multicenter, Single-arm Study To Investigate The Efficacy And Safety Of Atezolizumab As Neoadjuvant And Adjuvant Therapy In Patients With Stage IB, II, Or IIIA Resectable And Untreated Non-Small Cell Lung Cancer

STUDY 2017-152

Phase II

Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

STUDY 2018-120

Phase I/II

An Open Label, Single Arm, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination with Pembrolizumab in Patients with Advanced or Metastatic Post-PD-1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma

STUDY 2019-020

Phase III

A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)

STUDY 2019-034

Phase III

A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

STUDY 2019-036

Phase III

A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed/Platinum Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer

STUDY 2018-065

Phase II

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144 or N-145) in Patients with Solid Tumors

STUDY 2018-015

Phase I/II

A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Or Metastatic Solid Tumors

STUDY 2018-111

Phase III

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

STUDY 2018-060

Phase II

A Phase 2, Multicenter, Open-Label, 2-Cohort Study of Trastuzumab Deruxtecan (DS-8201a), an anti-HER2 Antibody Drug Conjugate (ADC), for HER2-Over-Expressing or -Mutated, Unresectable and/or Metastatic Non-Small Cell Lung Cancer (NSCLC)

STUDY 2018-098

Phase I/II

A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Anti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected Solid Tumors

STAGE IV

ALK

STUDY 2018-080

Phase II

Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

EGFR

STUDY 2017-145

Phase II

A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)

Other Genetic Marker

STUDY 2017-145

Phase II

A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)

STUDY 2015-174

Pilot

Study of the Effects of Dexamethasone on Non-Small Cell Lung Cancer Using [F-18] FLT for Imaging with Positron Emission Pilot Tomography (PET)

STUDY 2018-065

Phase II

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144 or N-145) in Patients with Solid Tumors

STUDY 2018-120

Phase I/II

An Open Label, Single Arm, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination with Pembrolizumab in Patients with Advanced or Metastatic Post-PD-1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma

STUDY 2017-111

Phase I

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

STUDY 2016-017

Phase I/II

A Phase 1B/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab* (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies

STUDY 2016-055

Phase I

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY 2014-002

Phase II

A Study to Assess the Ability to Initiate Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Based on Genomic Analyses of Tumor Specimens

STUDY 2016-037

Phase I

A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

STUDY 2018-060**Phase II**

A Phase 2, Multicenter, Open-Label, 2-Cohort Study of Trastuzumab Deruxtecan (DS-8201a), an anti-HER2 Antibody Drug Conjugate (ADC), for HER2-Over-Expressing or -Mutated, Unresectable and/or Metastatic Non-Small Cell Lung Cancer (NSCLC)

STUDY 2018-015**Phase I/II**

A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Or Metastatic Solid Tumors

STUDY 2017-129**NA**

Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List

STUDY 2018-053**Phase III**

METIS: Pivotal, Open-Label, Randomized Study of Radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-Small Cell Lung Cancer (NSCLC)

STUDY 2018-098**Phase I/II**

A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Anti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected Solid Tumors

RECURRENT**ALK****STUDY 2017-106****Phase II**

Phase II Multi-Center Study of Pembrolizumab in Combination with Platinumbased Doublet Chemotherapy in Patients with EGFR Mutation and ALK Positive NSCLC (Non-Small Cell Lung Cancer) with Progressive Disease Following Prior Tyrosine Kinase Inhibitors (TKIs)

EGFR**STUDY 2017-106****Phase II**

Phase II Multi-Center Study of Pembrolizumab in Combination with Platinumbased Doublet Chemotherapy in Patients with EGFR Mutation and ALK Positive NSCLC (Non-Small Cell Lung Cancer) with Progressive Disease Following Prior Tyrosine Kinase Inhibitors (TKIs)

Other Genetic Marker**STUDY 2018-015****Phase I/II**

A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Or Metastatic Solid Tumors

STUDY 2018-065**Phase II**

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144 or N-145) in Patients with Solid Tumors

SCLC LIMITED**STUDY NRG-LU005****Phase I/II**

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab

SCLC EXTENSIVE

STUDY 2017-064

Phase I/II

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

MESOTHELIOMA

STUDY 2018-105

Phase II

Study of Nivolumab and Ramucirumab for Patients with Previously-Treated Mesothelioma

STUDY 2017-064

Phase I/II

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

OTHER

STUDY 2017-064

Phase I/II

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

STUDY 2018-081

Phase I

A Phase I Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of ZN-e4 (KP-673) in Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor (EGFR) Mutations

STUDY 2018-171

Phase II

A Phase II, Open Label, Multi-Dose Study of 89ZR-DF-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients with Metastatic Solid Tumors

STUDY 2018-076

Phase I/II

A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas

STUDY 2016-116

Phase II

A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors

STUDY 2017-069

Phase I/II

A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2017-029

Phase I

An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours

STUDY 2017-087

Phase I

A Phase 1, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult Patients with Advanced Malignancies

STUDY NEW 2019-088

Phase I/II

A Phase 1b/2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 and Cobimetinib

in Adult Participants With Relapsed/Refractory Solid Tumors With Specific Genomic Aberrations

STUDY 2019-032

Phase I

A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy

STUDY 2018-167

Phase I

Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer

[RETURN TO TOP](#)

Karmanos Cancer Institute
4100 John R
Detroit, Michigan 48201
1-800-KARMANOS
(1-800-527-6266)
karmanos.org

To refer a patient or for more information on open clinical trials at the Karmanos Cancer Institute, call **1-800-Karmanos** (1-800-527-6266)

To schedule an appointment, please call between 7:30 AM – 5:30 PM, Monday – Friday

[FORWARD TO A COLLEAGUE](#)

[SUBSCRIBE TO KARMANOS CLINICAL TRIALS](#)



©2016 Karmanos Cancer Institute

This email was sent to lowed@karmanos.org. To ensure that you continue receiving our emails, please add us to your address book or safe list.

[manage](#) your preferences | [opt out](#) using TrueRemove®.

Got this as a forward? [Sign up](#) to receive our future emails.